Among 38 second line treated MCRC pts evaluated for KRAS genotype, 21 wild-type (55.3%) and 17 mutant (44.7%), demographic and baseline features were, respectively: male/female ratio, 17/4 and 8/9; metachronous/synchronous metastatic disease, 10/11 (48/52%) and 5/12 (29/71%) pts. This evidence concerns the gene KRAS and metastatic neoplasm.